

BCCA Protocol Summary for Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract Using Octreotide (SANDOSTATIN LAR[®])

Protocol Code

UGIOCTLAR

Tumour Group

GI

Contact Physician

GI Systemic Therapy

ELIGIBILITY:

- Functional neuroendocrine tumours of the mid-gut or pancreas (including carcinoid tumours and VIPoma), with symptoms due to ectopic hormone secretion (flushes, diarrhea, wheezing, etc.)
- A BCCA Compassionate Access Program (CAP) request with appropriate clinical information for each patient must be approved prior to treatment. **Re-approval through CAP will be required annually.**

EXCLUSIONS:

- Pregnant or lactating women

TESTS:

- No specific tests apart from those required to monitor the underlying disease
- A pretreatment ultrasound of the gall bladder is recommended to rule out the formation of gallstones. Repeat every 6 months while on therapy.

PREMEDICATIONS:

- Not usually required

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Octreotide (SANDOSTATIN LAR [®])	20mg	Intramuscular (deep intragluteal*) injection

*May use quadriceps for self-administration

Repeat every four weeks **until tumour progression**. Treatment may be started while patient is receiving octreotide daily SC injections. These should be continued for two weeks after the first octreotide monthly IM injection.

DOSE MODIFICATIONS:

For patients in whom symptoms are not fully controlled within the 4 weeks, the dose of octreotide (SANDOSTATIN LAR[®]) may be increased to **a maximum of 30 mg** every 4 weeks.

PRECAUTIONS:

- Concomitant diabetes:** Patients on oral hypoglycemics or insulin should be monitored closely for changes in blood glucose levels for several days after the start of octreotide (SANDOSTATIN LAR[®]) to determine the need for any dosage adjustments.
- Previous history of gallstones.**

- **Potential for some impairment in thyroid function:** monitor for signs and symptoms of hypothyroidism.

Call the GI Systemic Therapy physician in your regional cancer centre or Dr. Sanjay Rao at (250) 712-3900 or 1-888-563-7773 with any problems or questions regarding this treatment program.

Date activated: 01 July 1999

Date revised: 01 November 2011 (Eligibility revised to require CAP approval)